Delivery of neurotherapeutics across the blood brain barrier in stroke

Current Pharmaceutical Design

Volumn 18, Issue 25, 2012, Pages 3704-3720

  Hu, Xiaoming ^a,b   Zhang, Meijuan ^b   Leak, Rehana K ^c   Gan, Yu ^a,b   Li, Peiying ^a,b   Gao, Yanqin ^a   Chen, Jun ^a,b,d  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c DUQUESNE UNIVERSITY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Blood brain barrier; Cell penetrating peptide; Neuroprotection; Stroke; TAT protein transduction domains

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CELL PENETRATING PEPTIDE; CENTRAL NERVOUS SYSTEM AGENTS; CHOLINE ACETYLTRANSFERASE; CILIARY NEUROTROPHIC FACTOR; CIPROFLOXACIN; COUMARIN; DIHYDROLIPOAMIDE DEHYDROGENASE; DOXORUBICIN; DRUG CARRIER; ERYTHROPOIETIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HEAT SHOCK PROTEIN 70; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; INSULIN RECEPTOR; LEPTIN; NANOPARTICLE; NEUROGLOBIN; PENETRATIN; POSTSYNAPTIC DENSITY PROTEIN 95; PROTEGRIN; PROTEIN BCL X; PROTEIN KINASE C; PROTEIN NOGO A; RITONAVIR; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; SUPEROXIDE DISMUTASE; TRANSFERRIN RECEPTOR; UNINDEXED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ATAXIA TELANGIECTASIA; BLOOD BRAIN BARRIER; CELL ORGANELLE; CELL TYPE; CEREBROVASCULAR ACCIDENT; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; FEASIBILITY STUDY; HUMAN; IMMUNOCOMPETENT CELL; MICELLE; NEUROPROTECTION; NONHUMAN; POSTSYNAPTIC DENSITY; PRIORITY JOURNAL; PROTEIN STABILITY; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; ANTITHROMBINS; BLOOD-BRAIN BARRIER; DRUG CARRIERS; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES; STROKE;

EID: 84867504144     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212802002715     Document Type: Review

References (188)

1. Bechmann I, Galea I, Perry VH. What is the blood-brain barrier (not)? Trends Immunol 2007; 28: 5-11.
2. Liddelow SA. Fluids and barriers of the CNS: a historical viewpoint. Fluids Barriers CNS 2011; 8: 2.
3. Kim JA, Tran ND, Li Z, Yang F, Zhou W, Fisher MJ. Brain endothelial hemostasis regulation by pericytes. J Cereb Blood Flow Metab 2006; 26: 209-17.
4. Brownson EA, Abbruscato TJ, Gillespie TJ, Hruby VJ, Davis TP. Effect of peptidases at the blood brain barrier on the permeability of enkephalin. J Pharmacol Exp Ther 1994; 270: 675-80.
5. Loscher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2005; 2: 86-98.
6. Neuwelt EA, Dahlborg SA. Chemotherapy administered in conjunction with osmotic blood-brain barrier modification in patients with brain metastases. J Neurooncol 1987; 4: 195-207.
7. Lin S, Fan LW, Rhodes PG, Cai Z. Intranasal administration of IGF-1 attenuates hypoxic-ischemic brain injury in neonatal rats. Exp Neurol 2009; 217: 361-70.
8. Namanja HA, Emmert D, Pires MM, Hrycyna CA, Chmielewski J. Inhibition of human P-glycoprotein transport and substrate binding using a galantamine dimer. Biochem Biophys Res Commun 2009; 388: 672-6.
9. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999; 285: 1569-72.
10. Kordower JH, Charles V, Bayer R, et al. Intravenous administration of a transferrin receptor antibody-nerve growth factor conjugate prevents the degeneration of cholinergic striatal neurons in a model of Huntington disease. Proc Natl Acad Sci USA 1994; 91: 9077-80.
11. Shi N, Pardridge WM. Noninvasive gene targeting to the brain. Proc Natl Acad Sci USA 2000; 97: 7567-72.
12. Silva GA. Nanotechnology approaches for drug and small molecule delivery across the blood brain barrier. Surg Neurol 2007; 67: 113-6.
13. Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988; 55: 1189-93.
14. Joliot A, Pernelle C, Deagostini-Bazin H, Prochiantz A. Antennapedia homeobox peptide regulates neural morphogenesis. Proc Natl Acad Sci USA 1991; 88: 1864-8.
15. Pooga M, Hallbrink M, Zorko M, Langel U. Cell penetration by transportan. Faseb J 1998; 12: 67-77.
16. Andaloussi SE, Lehto T, Mager I, et al. Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Res; 39: 3972-87.
17. Chaloin L, Vidal P, Heitz A, et al. Conformations of primary amphipathic carrier peptides in membrane mimicking environments. Biochemistry 1997; 36: 11179-87.
18. Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, Rothbard JB. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci USA 2000; 97: 13003-8.
19. Youn JI, Park SH, Jin HT, et al. Enhanced delivery efficiency of recombinant adenovirus into tumor and mesenchymal stem cells by a novel PTD. Cancer Gene Ther 2008; 15: 703-12.
20. Mitchell DJ, Kim DT, Steinman L, Fathman CG, Rothbard JB. Polyarginine enters cells more efficiently than other polycationic homopolymers. J Pept Res 2000; 56: 318-25.
21. Carrigan CN, Imperiali B. The engineering of membranepermeable peptides. Anal Biochem 2005; 341: 290-8.
22. Vives E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 1997; 272: 16010-7.
23. Derossi D, Joliot AH, Chassaing G, Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 1994; 269: 10444-50.
24. Elliott G, O'Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 1997; 88: 223-33.
25. Rousselle C, Clair P, Lefauconnier JM, Kaczorek M, Scherrmann JM, Temsamani J. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol Pharmacol 2000; 57: 679-86.
26. Elmquist A, Lindgren M, Bartfai T, Langel U. VE-cadherinderived cell-penetrating peptide, pVEC, with carrier functions. Exp Cell Res 2001; 269: 237-44.
27. Foerg C, Ziegler U, Fernandez-Carneado J, et al. Decoding the entry of two novel cell-penetrating peptides in HeLa cells: lipid raft-mediated endocytosis and endosomal escape. Biochemistry 2005; 44: 72-81.
28. Neundorf I, Rennert R, Franke J, Kozle I, Bergmann R. Detailed analysis concerning the biodistribution and metabolism of human calcitonin-derived cell-penetrating peptides. Bioconjug Chem 2008; 19: 1596-603.
29. Niarchos DK, Perez SA, Papamichail M. Characterization of a novel cell penetrating peptide derived from Bag-1 protein. Peptides 2006; 27: 2661-9.
30. Duchardt F, Ruttekolk IR, Verdurmen WP, et al. A cell-penetrating peptide derived from human lactoferrin with conformationdependent uptake efficiency. J Biol Chem 2009; 284: 36099-108.
31. Radis-Baptista G, de la Torre BG, Andreu D. A novel cellpenetrating peptide sequence derived by structural minimization of a snake toxin exhibits preferential nucleolar localization. J Med Chem 2008; 51: 7041-4.
32. Jha D, Mishra R, Gottschalk S, et al. CyLoP-1: a novel cysteinerich cell-penetrating peptide for cytosolic delivery of cargoes. Bioconjug Chem 2011; 22: 319-28.
33. Falanga A, Vitiello MT, Cantisani M, et al. A peptide derived from herpes simplex virus type 1 glycoprotein H: membrane translocation and applications to the delivery of quantum dots. Nanomedicine 2011; 7: 925-34.
34. Oehlke J, Wallukat G, Wolf Y, et al. Enhancement of intracellular concentration and biological activity of PNA after conjugation with a cell-penetrating synthetic model peptide. Eur J Biochem 2004; 271: 3043-9.
35. Rhee M, Davis P. Mechanism of uptake of C105Y, a novel cellpenetrating peptide. J Biol Chem 2006; 281: 1233-40.
36. El-Andaloussi S, Johansson HJ, Holm T, Langel U. A novel cellpenetrating peptide, M918, for efficient delivery of proteins and peptide nucleic acids. Mol Ther 2007; 15: 1820-6.
37. Sheng J, Oyler G, Zhou B, Janda K, Shoemaker CB. Identification and characterization of a novel cell-penetrating peptide. Biochem Biophys Res Commun 2009; 382: 236-40.
38. Crombez L, Aldrian-Herrada G, Konate K, et al. A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells. Mol Ther 2009; 17: 95-103.
39. Morris MC, Vidal P, Chaloin L, Heitz F, Divita G. A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res 1997; 25: 2730-6.
40. Soomets U, Lindgren M, Gallet X, et al. Deletion analogues of transportan. Biochim Biophys Acta 2000; 1467: 165-76.
41. Morris MC, Depollier J, Mery J, Heitz F, Divita G. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 2001; 19: 1173-6.
42. Mano M, Teodosio C, Paiva A, Simoes S, Pedroso de Lima MC. On the mechanisms of the internalization of S4(13)-PV cellpenetrating peptide. Biochem J 2005; 390: 603-12.
43. Cao G, Pei W, Ge H, et al. In vivo Delivery of a Bcl-xL Fusion Protein Containing the TAT Protein Transduction Domain Protects against Ischemic Brain Injury and Neuronal Apoptosis. J Neurosci 2002; 22: 5423-31.
44. Green M, Loewenstein PM. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat transactivator protein. Cell 1988; 55: 1179-88.
45. Fawell S, Seery J, Daikh Y, et al. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA 1994; 91: 664-8.
46. Brooks H, Lebleu B, Vives E. Tat peptide-mediated cellular delivery: back to basics. Adv Drug Deliv Rev 2005; 57: 559-77.
47. Vazquez J, Sun C, Du J, Fuentes L, Sumners C, Raizada MK. Transduction of a functional domain of the AT1 receptor in neurons by HIV-Tat PTD. Hypertension 2003; 41: 751-6.
48. Flinterman M, Farzaneh F, Habib N, Malik F, Gaken J, Tavassoli M. Delivery of therapeutic proteins as secretable TAT fusion products. Mol Ther 2009; 17: 334-42.
49. Yamano S, Dai J, Yuvienco C, Khapli S, Moursi AM, Montclare JK. Modified Tat peptide with cationic lipids enhances gene transfection efficiency via temperature-dependent and caveolaemediated endocytosis. J Control Release 2011; 152: 278-85.
50. Eum WS, Kim DW, Hwang IK, et al. In vivo protein transduction: biologically active intact pep-1-superoxide dismutase fusion protein efficiently protects against ischemic insult. Free Radic Biol Med 2004; 37: 1656-69.
51. Cho JH, Hwang IK, Yoo KY, et al. Effective delivery of Pep-1-cargo protein into ischemic neurons and long-term neuroprotection of Pep-1-SOD1 against ischemic injury in the gerbil hippocampus. Neurochem Int 2008; 52: 659-68.
52. Hwang IK, Eum WS, Yoo KY, et al. Copper chaperone for Cu,Zn-SOD supplement potentiates the Cu,Zn-SOD function of neuroprotective effects against ischemic neuronal damage in the gerbil hippocampus. Free Radic Biol Med 2005; 39: 392-402.
53. Yune TY, Lee JY, Jiang MH, Kim DW, Choi SY, Oh TH. Systemic administration of PEP-1-SOD1 fusion protein improves functional recovery by inhibition of neuronal cell death after spinal cord injury. Free Radic Biol Med 2008; 45: 1190-200.
54. Kim W, Kim DW, Yoo DY, et al. Neuroprotective Effects of PEP-1-Cu,Zn-SOD against Ischemic Neuronal Damage in the Rabbit Spinal Cord. Neurochem Res 2012; 37(2): 307-13.
55. Choi SH, Kim DW, Kim SY, et al. Transduced human copper chaperone for Cu,Zn-SOD (PEP-1-CCS) protects against neuronal cell death. Mol Cells 2005; 20: 401-8.
56. An JJ, Lee YP, Kim SY, et al. Transduced human PEP-1-heat shock protein 27 efficiently protects against brain ischemic insult. Febs J 2008; 275: 1296-308.
57. Kim DW, Jeong HJ, Kang HW, et al. Transduced human PEP-1-catalase fusion protein attenuates ischemic neuronal damage. Free Radic Biol Med 2009; 47: 941-52.
58. Kim DW, Kim DS, Kim MJ, et al. Imipramine enhances neuroprotective effect of PEP-1-Catalase against ischemic neuronal damage. BMB Rep 2011; 44: 647-52.
59. Perez F, Joliot A, Bloch-Gallego E, Zahraoui A, Triller A, Prochiantz A. Antennapedia homeobox as a signal for the cellular internalization and nuclear addressing of a small exogenous peptide. J Cell Sci 1992; 102 (Pt 4): 717-22.
60. Qian YQ, Billeter M, Otting G, Muller M, Gehring WJ, Wuthrich K. The structure of the Antennapedia homeodomain determined by NMR spectroscopy in solution: comparison with prokaryotic repressors. Cell 1989; 59: 573-80.
61. Fan YF, Lu CZ, Xie J, Zhao YX, Yang GY. Apoptosis inhibition in ischemic brain by intraperitoneal PTD-BIR3-RING (XIAP). Neurochem Int 2006; 48: 50-9.
62. Fan Y, Shi L, Gu Y, et al. Pretreatment with PTD-calbindin D 28k alleviates rat brain injury induced by ischemia and reperfusion. J Cereb Blood Flow Metab 2007; 27: 719-28.
63. Huang R, Yang W, Jiang C, Pei Y. Gene delivery into brain capillary endothelial cells using Antp-modified DNA-loaded nanoparticles. Chem Pharm Bull (Tokyo) 2006; 54: 1254-8.
64. Harwig SS, Swiderek KM, Lee TD, Lehrer RI. Determination of disulphide bridges in PG-2, an antimicrobial peptide from porcine leukocytes. J Pept Sci 1995; 1: 207-15.
65. Aumelas A, Mangoni M, Roumestand C, et al. Synthesis and solution structure of the antimicrobial peptide protegrin-1. Eur J Biochem 1996; 237: 575-83.
66. Sokolov Y, Mirzabekov T, Martin DW, Lehrer RI, Kagan BL. Membrane channel formation by antimicrobial protegrins. Biochim Biophys Acta 1999; 1420: 23-9.
67. Rousselle C, Smirnova M, Clair P, et al. Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: saturation kinetics and specificity. J Pharmacol Exp Ther 2001; 296: 124-31.
68. Rousselle C, Clair P, Temsamani J, Scherrmann JM. Improved brain delivery of benzylpenicillin with a peptide-vector-mediated strategy. J Drug Target 2002; 10: 309-15.
69. Rousselle C, Clair P, Smirnova M, et al. Improved brain uptake and pharmacological activity of dalargin using a peptide-vectormediated strategy. J Pharmacol Exp Ther 2003; 306: 371-6.
70. Drin G, Rousselle C, Scherrmann JM, Rees AR, Temsamani J. Peptide delivery to the brain via adsorptive-mediated endocytosis: advances with SynB vectors. AAPS PharmSci 2002; 4: E26.
71. Hearst SM, Walker LR, Shao Q, Lopez M, Raucher D, Vig PJ. The design and delivery of a thermally responsive peptide to inhibit S100B-mediated neurodegeneration. Neuroscience 2011; 197: 369-80.
72. Richard JP, Melikov K, Vives E, et al. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem 2003; 278: 585-90.
73. Du L, Kayali R, Bertoni C, et al. Arginine-rich cell-penetrating peptide dramatically enhances AMO-mediated ATM aberrant splicing correction and enables delivery to brain and cerebellum. Hum Mol Genet 2011; 20: 3151-60.
74. Kobayashi N, Niwa M, Hao Y, Yoshida T. Nucleolar localization signals of LIM kinase 2 function as a cell-penetrating peptide. Protein Pept Lett 2010; 17: 1480-8.
75. Jefferies WA, Brandon MR, Hunt SV, Williams AF, Gatter KC, Mason DY. Transferrin receptor on endothelium of brain capillaries. Nature 1984; 312: 162-3.
76. Pardridge WM. Non-invasive drug delivery to the human brain using endogenous blood-brain barrier transport systems. Pharm Sci Technolo Today 1999; 2: 49-59.
77. Zhang Y, Pardridge WM. Neuroprotection in transient focal brain ischemia after delayed intravenous administration of brain-derived neurotrophic factor conjugated to a blood-brain barrier drug targeting system. Stroke 2001; 32: 1378-84.
78. Wu D, Pardridge WM. Neuroprotection with noninvasive neurotrophin delivery to the brain. Proc Natl Acad Sci USA 1999; 96: 254-9.
79. Song BW, Vinters HV, Wu D, Pardridge WM. Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector. J Pharmacol Exp Ther 2002; 301: 605-10.
80. Boado RJ, Hui EK, Lu JZ, Pardridge WM. Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse. J Pharmacol Exp Ther; 333: 961-9.
81. Fu A, Hui EK, Lu JZ, Boado RJ, Pardridge WM. Neuroprotection in experimental stroke in the rat with an IgG-erythropoietin fusion protein. Brain Res 2010; 1360: 193-7.
82. Boado RJ, Zhang Y, Wang Y, Pardridge WM. GDNF fusion protein for targeted-drug delivery across the human blood-brain barrier. Biotechnol Bioeng 2008; 100: 387-96.
83. Asoh S, Ohsawa I, Mori T, et al. Protection against ischemic brain injury by protein therapeutics. Proc Natl Acad Sci USA 2002; 99: 17107-12.
84. Kreuter J, Ramge P, Petrov V, et al. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res 2003; 20: 409-16.
85. Ulbrich K, Hekmatara T, Herbert E, Kreuter J. Transferrin-and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm 2009; 71: 251-6.
86. Michaelis K, Hoffmann MM, Dreis S, et al. Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther 2006; 317: 1246-53.
87. Gelperina SE, Khalansky AS, Skidan IN, et al. Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicol Lett 2002; 126: 131-41.
88. Reddy MK, Labhasetwar V. Nanoparticle-mediated delivery of superoxide dismutase to the brain: an effective strategy to reduce ischemia-reperfusion injury. FASEB J 2009; 23: 1384-95.
89. Agemy L, Friedmann-Morvinski D, Kotamraju VR, et al. Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma. Proc Natl Acad Sci USA; 108: 17450-5.
90. Wilson B, Samanta MK, Santhi K, Kumar KP, Paramakrishnan N, Suresh B. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease. Brain Res 2008; 1200: 159-68.
91. Kurakhmaeva KB, Djindjikhashvili IA, Petrov VE, et al. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. J Drug Target 2009; 17: 564-74.
92. Hillaireau H, Couvreur P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci 2009; 66: 2873-96.
93. Kreuter J, Shamenkov D, Petrov V, et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target 2002; 10: 317-25.
94. Biju K, Zhou Q, Li G, et al. Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease. Mol Ther 2010; 18: 1536-44.
95. Baek SK, Makkouk AR, Krasieva T, Sun CH, Madsen SJ, Hirschberg H. Photothermal treatment of glioma; an in vitro study of macrophage-mediated delivery of gold nanoshells. J Neurooncol 2011; 104: 439-48.
96. Barone FC, Feuerstein GZ. Inflammatory mediators and stroke: new opportunities for novel therapeutics. J Cereb Blood Flow Metab 1999; 19: 819-34.
97. Cai B, Lin Y, Xue XH, Fang L, Wang N, Wu ZY. TAT-mediated delivery of neuroglobin protects against focal cerebral ischemia in mice. Exp Neurol 2011; 227: 224-31.
98. Kilic E, Dietz GP, Hermann DM, Bahr M. Intravenous TAT-Bcl-Xl is protective after middle cerebral artery occlusion in mice. Ann Neurol 2002; 52: 617-22.
99. Kilic U, Kilic E, Dietz GP, Bahr M. Intravenous TAT-GDNF is protective after focal cerebral ischemia in mice. Stroke 2003; 34: 1304-10.
100. Guegan C, Braudeau J, Couriaud C, et al. PTD-XIAP protects against cerebral ischemia by anti-apoptotic and transcriptional regulatory mechanisms. Neurobiol Dis 2006; 22: 177-86.
101. Bright R, Steinberg GK, Mochly-Rosen D. DeltaPKC mediates microcerebrovascular dysfunction in acute ischemia and in chronic hypertensive stress in vivo. Brain Res 2007; 1144: 146-55.
102. Doeppner TR, Dietz GP, El Aanbouri M, et al. TAT-Bcl-x(L) improves survival of neuronal precursor cells in the lesioned striatum after focal cerebral ischemia. Neurobiol Dis 2009; 34: 87-94.
103. Doeppner TR, El Aanbouri M, Dietz GP, Weise J, Schwarting S, Bahr M. Transplantation of TAT-Bcl-xL-transduced neural precursor cells: long-term neuroprotection after stroke. Neurobiol Dis; 40: 265-76.
104. Backman CM, Shan L, Zhang YJ, et al. Gene expression patterns for GDNF and its receptors in the human putamen affected by Parkinson's disease: a real-time PCR study. Mol Cell Endocrinol 2006; 252: 160-6.
105. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000; 97: 10526-31.
106. Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002; 8: 495-505.
107. Brines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue protection through an erythropoietin and common betasubunit heteroreceptor. Proc Natl Acad Sci USA 2004; 101: 14907-12.
108. Zhang F, Signore AP, Zhou Z, Wang S, Cao G, Chen J. Erythropoietin protects CA1 neurons against global cerebral ischemia in rat: potential signaling mechanisms. J Neurosci Res 2006; 83: 1241-51.
109. Koponen S, Goldsteins G, Keinanen R, Koistinaho J. Induction of protein kinase Cdelta subspecies in neurons and microglia after transient global brain ischemia. J Cereb Blood Flow Metab 2000; 20: 93-102.
110. Brodie C, Blumberg PM. Regulation of cell apoptosis by protein kinase c delta. Apoptosis 2003; 8: 19-27.
111. Majumder PK, Pandey P, Sun X, et al. Mitochondrial translocation of protein kinase C delta in phorbol ester-induced cytochrome c release and apoptosis. J Biol Chem 2000; 275: 21793-6.
112. Bates E, Bode C, Costa M, et al. Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation 2008; 117: 886-96.
113. Shimohata T, Zhao H, Steinberg GK. Epsilon PKC may contribute to the protective effect of hypothermia in a rat focal cerebral ischemia model. Stroke 2007; 38: 375-80.
114. Della-Morte D, Raval AP, Dave KR, Lin HW, Perez-Pinzon MA. Post-ischemic activation of protein kinase C epsilon protects the hippocampus from cerebral ischemic injury via alterations in cerebral blood flow. Neurosci Lett 2011; 487: 158-62.
115. Borsello T, Clarke PG, Hirt L, et al. A peptide inhibitor of c-Jun Nterminal kinase protects against excitotoxicity and cerebral ischemia. Nat Med 2003; 9: 1180-6.
116. Repici M, Centeno C, Tomasi S, et al. Time-course of c-Jun Nterminal kinase activation after cerebral ischemia and effect of DJNKI1 on c-Jun and caspase-3 activation. Neuroscience 2007; 150: 40-9.
117. Wiegler K, Bonny C, Coquoz D, Hirt L. The JNK inhibitor XG-102 protects from ischemic damage with delayed intravenous administration also in the presence of recombinant tissue plasminogen activator. Cerebrovasc Dis 2008; 26: 360-6.
118. Sheng M. The postsynaptic NMDA-receptor--PSD-95 signaling complex in excitatory synapses of the brain. J Cell Sci 2001; 114: 1251.
119. Aarts M, Liu Y, Liu L, et al. Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions. Science 2002; 298: 846-50.
120. Sun HS, Doucette TA, Liu Y, et al. Effectiveness of PSD95 inhibitors in permanent and transient focal ischemia in the rat. Stroke 2008; 39: 2544-53.
121. Sun Y, Jin K, Mao XO, Zhu Y, Greenberg DA. Neuroglobin is upregulated by and protects neurons from hypoxic-ischemic injury. Proc Natl Acad Sci USA 2001; 98: 15306-11.
122. Gou X, Wang Q, Yang Q, Xu L, Xiong L. TAT-NEP1-40 as a novel therapeutic candidate for axonal regeneration and functional recovery after stroke. J Drug Target 2011; 19: 86-95.
123. Wang Q, Gou X, Xiong L, et al. Trans-activator of transcriptionmediated delivery of NEP1-40 protein into brain has a neuroprotective effect against focal cerebral ischemic injury via inhibition of neuronal apoptosis. Anesthesiology 2008; 108: 1071-80.
124. Doeppner TR, Nagel F, Dietz GP, et al. TAT-Hsp70-mediated neuroprotection and increased survival of neuronal precursor cells after focal cerebral ischemia in mice. J Cereb Blood Flow Metab 2009; 29: 1187-96.
125. Ye N, Liu S, Lin Y, Rao P. Protective effects of intraperitoneal injection of TAT-SOD against focal cerebral ischemia/reperfusion injury in rats. Life Sci 2011; 89: 868-74.
126. Yin W, Cao G, Johnnides MJ, et al. TAT-mediated delivery of BclxL protein is neuroprotective against neonatal hypoxic-ischemic brain injury via inhibition of caspases and AIF. Neurobiol Dis 2006; 21: 358-71.
127. Dietz GP, Valbuena PC, Dietz B, et al. Application of a bloodbrain-barrier-penetrating form of GDNF in a mouse model for Parkinson's disease. Brain Res 2006; 1082: 61-6.
128. Nijboer CH, van der Kooij MA, van Bel F, Ohl F, Heijnen CJ, Kavelaars A. Inhibition of the JNK/AP-1 pathway reduces neuronal death and improves behavioral outcome after neonatal hypoxicischemic brain injury. Brain Behav Immun 2010; 24: 812-21.
129. Dykstra CM, Ratnam M, Gurd JW. Neuroprotection after status epilepticus by targeting protein interactions with postsynaptic density protein 95. J Neuropathol Exp Neurol 2009; 68: 823-31.
130. Nagel F, Falkenburger BH, Tonges L, et al. Tat-Hsp70 protects dopaminergic neurons in midbrain cultures and in the substantia nigra in models of Parkinson's disease. J Neurochem 2008; 105: 853-64.
131. Kim DW, Eum WS, Jang SH, et al. Transduced Tat-SOD fusion protein protects against ischemic brain injury. Mol Cells 2005; 19: 88-96.
132. Gao Y, Liang W, Hu X, et al. Neuroprotection against hypoxicischemic brain injury by inhibiting the apoptotic protease activating factor-1 pathway. Stroke 2010; 41: 166-72.
133. Nijboer CH, Heijnen CJ, Groenendaal F, van Bel F, Kavelaars A. Alternate pathways preserve tumor necrosis factor-alpha production after nuclear factor-kappaB inhibition in neonatal cerebral hypoxia-ischemia. Stroke 2009; 40: 3362-8.
134. Alves ID, Jiao CY, Aubry S, et al. Cell biology meets biophysics to unveil the different mechanisms of penetratin internalization in cells. Biochim Biophys Acta 2010; 1798: 2231-9.
135. Kim DW, Lee SH, Jeong MS, et al. Transduced Tat-SAG fusion protein protects against oxidative stress and brain ischemic insult. Free Radic Biol Med 2010; 48: 969-77.
136. Zhang C, Su Z, Zhao B, et al. Tat-modified leptin is more accessible to hypothalamus through brain-blood barrier with a significant inhibition of body-weight gain in high-fat-diet fed mice. Exp Clin Endocrinol Diabetes 2010; 118: 31-7.
137. Rapoport M, Salman L, Sabag O, Patel MS, Lorberboum-Galski H. Successful TAT-mediated enzyme replacement therapy in a mouse model of mitochondrial E3 deficiency. J Mol Med (Berl) 2011; 89: 161-70.
138. Smith DL, Pozueta J, Gong B, Arancio O, Shelanski M. Reversal of long-term dendritic spine alterations in Alzheimer disease models. Proc Natl Acad Sci USA 2009; 106: 16877-82.
139. Qu HY, Zhang T, Li XL, et al. Transducible P11-CNTF rescues the learning and memory impairments induced by amyloid-beta peptide in mice. Eur J Pharmacol 2008; 594: 93-100.
140. Fu AL, Li Q, Dong ZH, Huang SJ, Wang YX, Sun MJ. Alternative therapy of Alzheimer's disease via supplementation with choline acetyltransferase. Neurosci Lett 2004; 368: 258-62.
141. Berger C, Gremlich HU, Schmidt P, et al. In vivo monitoring the fate of Cy5.5-Tat labeled T lymphocytes by quantitative nearinfrared fluorescence imaging during acute brain inflammation in a rat model of experimental autoimmune encephalomyelitis. J Immunol Methods 2007; 323: 65-77.
142. Santra S, Yang H, Holloway PH, Stanley JT, Mericle RA. Synthesis of water-dispersible fluorescent, radio-opaque, and paramagnetic CdS:Mn/ZnS quantum dots: a multifunctional probe for bioimaging. J Am Chem Soc 2005; 127: 1656-7.
143. Santra S, Yang H, Dutta D, et al. TAT conjugated, FITC doped silica nanoparticles for bioimaging applications. Chem Commun (Camb) 2004: 2810-1.
144. Qin Y, Chen H, Yuan W, et al. Liposome formulated with TAT-modified cholesterol for enhancing the brain delivery. Int J Pharm 2011; 419: 85-95.
145. Kanazawa T, Taki H, Tanaka K, Takashima Y, Okada H. Cell-penetrating peptide-modified block copolymer micelles promote direct brain delivery via intranasal administration. Pharm Res 2011; 28: 2130-9.
146. Wang H, Xu K, Liu L, et al. The efficacy of self-assembled cationic antimicrobial peptide nanoparticles against Cryptococcus neoformans for the treatment of meningitis. Biomaterials 2010; 31: 2874-81.
147. Liu L, Venkatraman SS, Yang YY, et al. Polymeric micelles anchored with TAT for delivery of antibiotics across the bloodbrain barrier. Biopolymers 2008; 90: 617-23.
148. Liu L, Guo K, Lu J, et al. Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEGTAT for drug delivery across the blood-brain barrier. Biomaterials 2008; 29: 1509-17.
149. Rao KS, Reddy MK, Horning JL, Labhasetwar V. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials 2008; 29: 4429-38.
150. Nakase I, Niwa M, Takeuchi T, et al. Cellular uptake of argininerich peptides: roles for macropinocytosis and actin rearrangement. Mol Ther 2004; 10: 1011-22.
151. Lu JZ, Boado RJ, Hui EK, Zhou QH, Pardridge WM. Expression in CHO cells and pharmacokinetics and brain uptake in the Rhesus monkey of an IgG-iduronate-2-sulfatase fusion protein. Biotechnol Bioeng 2011; 108: 1954-64.
152. Boado RJ, Lu JZ, Hui EK, Pardridge WM. IgG-single chain Fv fusion protein therapeutic for Alzheimer's disease: Expression in CHO cells and pharmacokinetics and brain delivery in the rhesus monkey. Biotechnol Bioeng; 105: 627-35.
153. Futaki S, Suzuki T, Ohashi W, et al. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 2001; 276: 5836-40.
154. Mai JC, Shen H, Watkins SC, Cheng T, Robbins PD. Efficiency of protein transduction is cell type-dependent and is enhanced by dextran sulfate. J Biol Chem 2002; 277: 30208-18.
155. Suzuki T, Futaki S, Niwa M, Tanaka S, Ueda K, Sugiura Y. Possible existence of common internalization mechanisms among arginine-rich peptides. J Biol Chem 2002; 277: 2437-43.
156. Derossi D, Calvet S, Trembleau A, Brunissen A, Chassaing G, Prochiantz A. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J Biol Chem 1996; 271: 18188-93.
157. Deshayes S, Gerbal-Chaloin S, Morris MC, et al. On the mechanism of non-endosomial peptide-mediated cellular delivery of nucleic acids. Biochim Biophys Acta 2004; 1667: 141-7.
158. Prochiantz A. Messenger proteins: homeoproteins, TAT and others. Curr Opin Cell Biol 2000; 12: 400-6.
159. Herce HD, Garcia AE. Molecular dynamics simulations suggest a mechanism for translocation of the HIV-1 TAT peptide across lipid membranes. Proc Natl Acad Sci USA 2007; 104: 20805-10.
160. Ter-Avetisyan G, Tunnemann G, Nowak D, et al. Cell entry of arginine-rich peptides is independent of endocytosis. J Biol Chem 2009; 284: 3370-8.
161. Fittipaldi A, Ferrari A, Zoppe M, et al. Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins. J Biol Chem 2003; 278: 34141-9.
162. Richard JP, Melikov K, Brooks H, Prevot P, Lebleu B, Chernomordik LV. Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparan sulfate receptors. J Biol Chem 2005; 280: 15300-6.
163. Wadia JS, Stan RV, Dowdy SF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 2004; 10: 310-5.
164. Kaplan IM, Wadia JS, Dowdy SF. Cationic TAT peptide transduction domain enters cells by macropinocytosis. J Control Release 2005; 102: 247-53.
165. Khalil IA, Kogure K, Futaki S, Harashima H. High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression. J Biol Chem 2006; 281: 3544-51.
166. Saalik P, Elmquist A, Hansen M, et al. Protein cargo delivery properties of cell-penetrating peptides. A comparative study. Bioconjug Chem 2004; 15: 1246-53.
167. Chakrabarti R, Wylie DE, Schuster SM. Transfer of monoclonal antibodies into mammalian cells by electroporation. J Biol Chem 1989; 264: 15494-500.
168. Arnheiter H, Haller O. Antiviral state against influenza virus neutralized by microinjection of antibodies to interferon-induced Mx proteins. Embo J 1988; 7: 1315-20.
169. Lee YJ, Johnson G, Peltier GC, Pellois JP. A HA2-Fusion tag limits the endosomal release of its protein cargo despite causing endosomal lysis. Biochim Biophys Acta 2011; 1810: 752-8.
170. Derossi D, Chassaing G, Prochiantz A. Trojan peptides: the penetratin system for intracellular delivery. Trends Cell Biol 1998; 8: 84-7.
171. Kawamoto S, Takasu M, Miyakawa T, et al. Inverted micelle formation of cell-penetrating peptide studied by coarse-grained simulation: importance of attractive force between cell-penetrating peptides and lipid head group. J Chem Phys 2011; 134: 095103.
172. Simeoni F, Morris MC, Heitz F, Divita G. Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res 2003; 31: 2717-24.
173. Binder C, Read SP, Cashman SM, Kumar-Singh R. Nuclear targeted delivery of macromolecules to retina and cornea. J Gene Med 2011; 13: 158-70.
174. Del Gaizo V, Payne RM. A novel TAT-mitochondrial signal sequence fusion protein is processed, stays in mitochondria, and crosses the placenta. Mol Ther 2003; 7: 720-30.
175. Horton KL, Stewart KM, Fonseca SB, Guo Q, Kelley SO. Mitochondria-penetrating peptides. Chem Biol 2008; 15: 375-82.
176. Zhao K, Luo G, Giannelli S, Szeto HH. Mitochondria-targeted peptide prevents mitochondrial depolarization and apoptosis induced by tert-butyl hydroperoxide in neuronal cell lines. Biochem Pharmacol 2005; 70: 1796-806.
177. Xia H, Gao X, Gu G, L et al. Low molecular weight protaminefunctionalized nanoparticles for drug delivery to the brain after intranasal administration. Biomaterials 2011; 32: 9888-98.
178. Ko YT, Hartner WC, Kale A, Torchilin VP. Gene delivery into ischemic myocardium by double-targeted lipoplexes with antimyosin antibody and TAT peptide. Gene Ther 2009; 16: 52-9.
179. Nagahara H, Vocero-Akbani AM, Snyder EL, et al. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat Med 1998; 4: 1449-52.
180. Chauhan A, Tikoo A, Kapur AK, Singh M. The taming of the cell penetrating domain of the HIV Tat: myths and realities. J Control Release 2007; 117: 148-62.
181. Grunwald J, Rejtar T, Sawant R, Wang Z, Torchilin VP. TAT peptide and its conjugates: proteolytic stability. Bioconjug Chem 2009; 20: 1531-7.
182. Pujals S, Fernandez-Carneado J, Ludevid MD, Giralt E. D-SAP: a new, noncytotoxic, and fully protease resistant cell-penetrating peptide. ChemMedChem 2008; 3: 296-301.
183. Achilefu S, Srinivasan A, Schmidt MA, Jimenez HN, Bugaj JE, Erion JL. Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors. J Med Chem 2003; 46: 3403-11.
184. Meng H, Kumar K. Antimicrobial activity and protease stability of peptides containing fluorinated amino acids. J Am Chem Soc 2007; 129: 15615-22.
185. Kilk K, Mahlapuu R, Soomets U, Langel U. Analysis of in vitro toxicity of five cell-penetrating peptides by metabolic profiling. Toxicology 2009; 265: 87-95.
186. Cardozo AK, Buchillier V, Mathieu M, et al. Cell-permeable peptides induce dose-and length-dependent cytotoxic effects. Biochim Biophys Acta 2007; 1768: 2222-34.
187. El-Andaloussi S, Jarver P, Johansson HJ, Langel U. Cargodependent cytotoxicity and delivery efficacy of cell-penetrating peptides: a comparative study. Biochem J 2007; 407: 285-92.
188. Herve F, Ghinea N, Scherrmann JM. CNS delivery via adsorptive transcytosis. Aaps J 2008; 10: 455-72.